Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur

Nat Struct Mol Biol. 2020 Jun;27(6):529-532. doi: 10.1038/s41594-020-0440-6. Epub 2020 May 7.

Abstract

The antineoplastic drug carmofur is shown to inhibit the SARS-CoV-2 main protease (Mpro). Here, the X-ray crystal structure of Mpro in complex with carmofur reveals that the carbonyl reactive group of carmofur is covalently bound to catalytic Cys145, whereas its fatty acid tail occupies the hydrophobic S2 subsite. Carmofur inhibits viral replication in cells (EC50 = 24.30 μM) and is a promising lead compound to develop new antiviral treatment for COVID-19.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Betacoronavirus / drug effects
  • Betacoronavirus / enzymology*
  • COVID-19
  • Chlorocebus aethiops
  • Coronavirus 3C Proteases
  • Coronavirus Infections / virology
  • Cysteine Endopeptidases / chemistry*
  • Cysteine Endopeptidases / genetics
  • Cysteine Endopeptidases / metabolism
  • Fluorouracil / analogs & derivatives*
  • Fluorouracil / chemistry
  • Fluorouracil / pharmacology
  • Models, Molecular
  • Pandemics
  • Pneumonia, Viral / virology
  • SARS-CoV-2
  • Vero Cells
  • Viral Nonstructural Proteins / antagonists & inhibitors*
  • Viral Nonstructural Proteins / chemistry*
  • Viral Nonstructural Proteins / genetics
  • Viral Nonstructural Proteins / metabolism

Substances

  • Viral Nonstructural Proteins
  • Cysteine Endopeptidases
  • Coronavirus 3C Proteases
  • carmofur
  • Fluorouracil